At a glance
ClinicalIndex Comparison RecordN/ARecruiting· 2,000 target
Drug / intervention
PANcreatic cancer Exosome Early detectiON (PANXEON)other
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Early Detection of Pancreatic Cancer: Prospective Study
In Brief
An observational study evaluating PANcreatic cancer Exosome Early detectiON (PANXEON) for Pancreatic Cancer and 12 related conditions. Currently recruiting, targeting 2,000 participants across 11 sites in 3 countries.
Signals
Enrolling ahead of pace
Detailed Summary
This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer, Pancreatic Carcinoma, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Neoplasms, Pancreatic Cancer Stage I, Pancreatic Cancer Stage, Pancreatic Cancer Resectable, Pancreatic Cancer Stage 0, Pancreatic Cancer Stage II, Pancreatic Cancer Stage III, Pancreatic Cancer, Adult, Pancreatic Cancer Non-resectable
CountriesJapan, South Korea, United States
Collaborators--
Timeline
N/ARecruitingOverdue
202420252026
Enrollment StartMar 2023
First PostedApr 2024
Primary CompletionJun 2026
TodayJul 2026
First PostedApr 29, 2024
Enrollment StartMar 15, 2023
Primary CompletionJun 18, 2026
TodayJul 1, 2026
Enrollment to primary: 3.3 yearsPosted 2.2 years ago
Interventions
PANcreatic cancer Exosome Early detectiON (PANXEON)other
This test will utilize quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) to quantify the expression levels of 5 cell-free and 8 exosome-miRNAs in plasma samples obtained from patients with pancreatic ductal adenocarcinoma and from individuals without it